Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: A study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 95-103

  Gröschel, Stefan ^a   Schlenk, Richard F ^a   Engelmann, Jan ^a   Rockova, Veronika ^f   Teleanu, Veronica ^a   Kühn, Michael W M ^a   Eiwen, Karina ^a   Erpelinck, Claudia ^f   Havermans, Marije ^f   Lübbert, Michael ^b   Germing, Ulrich ^c   Schmidt Wolf, Ingo G H ^d   Beverloo, H Berna ^f,g   Schuurhuis, Gerrit J ^h   Ossenkoppele, Gert J ^h   Schlegelberger, Brigitte ^e   Verdonck, Leo F ⁱ   Vellenga, Edo ^j   Verhoef, Gregor ^k   Vandenberghe, Peter ^k   Pabst, Thomas ^l   Bargetzi, Mario ^m   Krauter, Jürgen ^e   Ganser, Arnold ^e   Valk, Peter J M ^f   Löwenberg, Bob ^f   Döhner, Konstanze ^a   Döhner, Hartmut ^a   Delwel, Ruud ^f   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Dutch Working Group on Hemato Oncologic Genome Diagnostics   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ISALA HOSPITAL   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF BERN   (Switzerland)

^m CANTONAL HOSPITAL AARAU   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ECOTROPIC VIRAL INTEGRATION 1 PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 11Q; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; TRISOMY 8;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 9; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENES; REMISSION INDUCTION; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84871820815     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5505     Document Type: Article

References (39)

1. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
2. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
3. Swerdlow S, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Geneva, Switzerland, WHO Press, 2008
4. Ayton PM, Cleary ML: Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17:2298-2307, 2003
5. Lane SW, Wang YJ, Lo Celso C, et al: Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 118:2849-2856, 2011
6. Milne TA, Briggs SD, Brock HW, et al: MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10:1107-1117, 2002
7. Rowley JD: The critical role of chromosome translocations in human leukemias. Annu Rev Genet 32:495-519, 1998
8. Tkachuk DC, Kohler S, Cleary ML: Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71:691-700, 1992
9. Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41-47, 2002
10. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 101:837-845, 2003
11. Gröschel S, Lugthart S, Schlenk RF, et al: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28:2101-2107, 2010
12. Goyama S, Yamamoto G, Shimabe M, et al: Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3:207-220, 2008
13. Morishita K, Parker DS, Mucenski ML, et al: Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54:831-840, 1988
14. Delwel R, Funabiki T, Kreider BL, et al: Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13:4291-4300, 1993
15. Krauter J, Wagner K, Schäfer I, et al: Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 27:3000-3006, 2009
16. HOVON: Dutch-Belgian Cooperative Trial Group for Hematology-Oncology. http://www.hovon.nl
17. Schlenk RF, Benner A, Hartmann F, et al: Risk-adapted postremission therapy in acute myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. Leukemia 17:1521-1528, 2003
18. Schlenk RF, Döhner K, Kneba M, et al: Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: Results from the AMLSG Trial AML HD98B. Haematologica 94:54-60, 2009
19. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008
20. Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010
21. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301, 2009
22. Döhner K, Tobis K, Ulrich R, et al: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254-3261, 2002
23. Gaidzik VI, Bullinger L, Schlenk RF, et al: RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 29:1364-1372, 2011
24. Gaidzik VI, Paschka P, Späth D, et al: TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML Study Group. J Clin Oncol 30:1350-1357, 2012
25. Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643, 2010
26. Stegelmann F, Bullinger L, Schlenk RF, et al: DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25:1217-1219, 2011
27. Thol F, Friesen I, Damm F, et al: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-2506, 2011
28. Jansen MW, van der Velden VH, van Dongen JJ: Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia 19:2016-2018, 2005
29. Scholl C, Schlenk RF, Eiwen K, et al: The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90:1626-1634, 2005
30. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
31. Therneau TM, Li H: Computing the Cox model for case cohort designs. Lifetime Data Anal 5:99-112, 1999
32. Mantel N, Byar D: Evaluation of response-time data involving transient states: An illustration using heart transplant data. J Am Stat Assoc 69:81-86, 1974
33. Cox DR: Regression models and life tables. J R Stat Soc 187-220, 1972
34. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer Verlag, 2001
35. Team RDC: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2007
36. Bindels EM, Havermans M, Lugthart S, et al: EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 119:5838-5849, 2012
37. Lugthart S, Gröschel S, Beverloo HB, et al: Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 28:3890-3898, 2010
38. Arai S, Yoshimi A, Shimabe M, et al: Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117:6304-6314, 2011
39. Krivtsov AV, Twomey D, Feng Z, et al: Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822, 2006